Approach to geriatric care in light of the introduction of Alzheimer disease modifying drugs

Abstract

Lecanemab with a novel mechanism for Alzheimer disease received approval in September 2023 in Japan. Lecanemab removes protofibrils, soluble aggregates of amyloid, considered the causative substance of Alzheimer disease, from the brain, hence termed a disease–modifying drug. Lecanemab garnered significant attention due to its entirely new pharmacological mechanism and its high cost. However, its actual impact in clinical settings remains uncertain. This paper discusses the potential number of individuals with dementia who may be eligible for Lecanemab treatment and examines factors to consider in its administration in real–world clinical practice. However, it has become apparent that there is still insufficient data accumulated for such discussions. A comprehensive survey is planned for all cases of Lecanemab administration. Alongside clinical experience, data accumulation is expected in the coming times. Until data is accumulated, a cautious approach is considered appropriate for Lecanemab administration.